The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
Information source: University of Utah
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Sepsis
Intervention: Linezolid or Vancomycin (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of Utah Official(s) and/or principal investigator(s):
Guy Zimmerman, MD, Principal Investigator, Affiliation: University of Utah
Overall contact:
Matthew Rondina, Phone: 801-213-2270, Email: matthew.rondina@hsc.utah.edu
Summary
We will determine if linezolid inhibits cellular activation and production of
pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and
the justification for further investigations in S. Aureus sepsis.
Clinical Details
Official title: The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
Study design: Other, Prospective
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy, taking no medications, and not recently hospitalized
Exclusion Criteria:
- Infection (active)
Locations and Contacts
Matthew Rondina, Phone: 801-213-2270, Email: matthew.rondina@hsc.utah.edu
University of Utah, Salt Lake City, Utah 84108, United States; Recruiting
Matthew Rondina, M.D., Phone: 801-581-7818, Email: matthew.rondina@hsc.utah.edu
Matthew T Rondina, M.D., Principal Investigator
Additional Information
Starting date: January 2009
Ending date: June 2010
Last updated: June 18, 2009
|
